Oncology Pharma Inc. (ONPH)
OTCMKTS
· Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
At close: May 13, 2025
Oncology Pharma Income Statement
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
Fiscal Year | FY 2013 | FY 2011 | FY 2004 | FY 2003 | FY 2002 | 1997 - 2001 |
|---|---|---|---|---|---|---|
Period Ending | Mar '13 Mar 31, 2013 | Jun '11 Jun 30, 2011 | Mar '04 Mar 31, 2004 | Mar '03 Mar 31, 2003 | Mar '02 Mar 31, 2002 | 1997 - 2001 |
| Revenue | 0.01 | 0.13 | 1.18 | 3.28 | 3.67 | Upgrade
|
| Revenue Growth (YoY) | -92.42% | -88.59% | -63.99% | -10.67% | -8.48% | Upgrade
|
| Cost of Revenue | - | - | 0.65 | 1.21 | 1.36 | Upgrade
|
| Gross Profit | 0.01 | 0.13 | 0.53 | 2.07 | 2.31 | Upgrade
|
| Selling, General & Admin | 0.02 | 0.02 | 1.85 | 2.91 | 3.56 | Upgrade
|
| Research & Development | - | - | 0.38 | 0.66 | 0.77 | Upgrade
|
| Operating Expenses | 0.02 | 0.08 | 2.23 | 3.57 | 4.33 | Upgrade
|
| Operating Income | -0.01 | 0.06 | -1.7 | -1.5 | -2.02 | Upgrade
|
| Interest & Investment Income | - | - | 0.01 | 0.02 | 0.09 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | 0.09 | - | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | -0.01 | - | -0.02 | Upgrade
|
| EBT Excluding Unusual Items | -0.01 | 0.06 | -1.71 | -1.4 | -1.95 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 0.14 | - | - | Upgrade
|
| Asset Writedown | - | - | - | -0.12 | - | Upgrade
|
| Pretax Income | -0.01 | 0.06 | -1.57 | -1.52 | -1.95 | Upgrade
|
| Income Tax Expense | 0 | 0 | - | - | - | Upgrade
|
| Earnings From Continuing Operations | -0.02 | 0.06 | -1.57 | -1.52 | -1.95 | Upgrade
|
| Earnings From Discontinued Operations | 0.2 | - | - | - | - | Upgrade
|
| Net Income | 0.19 | 0.06 | -1.57 | -1.52 | -1.95 | Upgrade
|
| Net Income to Common | 0.19 | 0.06 | -1.57 | -1.52 | -1.95 | Upgrade
|
| Net Income Growth | 216.79% | - | - | - | - | Upgrade
|
| Free Cash Flow | 0 | - | -2.02 | -1.59 | -1.77 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 44.62% | 63.05% | 63.02% | Upgrade
|
| Operating Margin | -141.66% | 44.19% | -144.03% | -45.85% | -54.90% | Upgrade
|
| Profit Margin | 1821.37% | 43.60% | -132.52% | -46.34% | -53.13% | Upgrade
|
| Free Cash Flow Margin | 7.25% | - | -170.79% | -48.51% | -48.28% | Upgrade
|
| EBITDA | -0.01 | - | -1.62 | -1.11 | -1.68 | Upgrade
|
| EBITDA Margin | -84.69% | - | -137.17% | -33.81% | -45.62% | Upgrade
|
| D&A For EBITDA | 0.01 | - | 0.08 | 0.4 | 0.34 | Upgrade
|
| EBIT | -0.01 | 0.06 | -1.7 | -1.5 | -2.02 | Upgrade
|
| EBIT Margin | -141.66% | 44.19% | -144.03% | -45.85% | -54.90% | Upgrade
|
| Effective Tax Rate | - | 1.34% | - | - | - | Upgrade
|
| Revenue as Reported | - | - | 1.18 | 3.28 | 3.67 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.